SCHEMBL7246567

SCHEMBL7246567

COc1ccc(S(=O)(=O)N2CC=CC(c3ccccc3)C2C(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
TSHR P16473 1/20 0.55
RECQL P46063 1/20 0.55
MAPT P10636 2/20 0.49
TAS2R14 Q9NYV8 3/20 0.47
MMP1 P03956 7/20 0.47
MMP3 P08254 7/20 0.47
MMP9 P14780 6/20 0.47
MMP7 P09237 2/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
MMP2 P08253 1/20 0.46
MMP13 P45452 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ADAM17 P78536 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7246571 1.00 LMNA (0.55) LMNAKDM4EALDH1A1TSHRRECQL
SCHEMBL7244524 0.89 MMP1 (0.57) MMP1MMP3MMP9MMP7MMP2
SCHEMBL7248829 0.84 MMP3 (0.50) MMP1MMP3MMP9MMP7MMP2
SCHEMBL8517198 0.84 MMP3 (0.50) MMP1MMP3MMP9MMP7MMP2
SCHEMBL7248830 0.84 MMP3 (0.50) MMP1MMP3MMP9MMP7MMP2
SCHEMBL7249697 0.83 MMP1 (0.50) LMNAKDM4EALDH1A1TSHRRECQL
SCHEMBL7249691 0.83 MMP1 (0.50) LMNAKDM4EALDH1A1TSHRRECQL
SCHEMBL6076031 0.78 MMP3 (0.47) TAS2R14MMP1MMP3MMP9MMP7
SCHEMBL6076042 0.76 CA12 (0.53) LMNAKDM4EALDH1A1TSHRRECQL
SCHEMBL7424316 0.76 MMP3 (0.48) MMP1MMP3MMP9MMP7MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6509337-B1 A method of treating a mammalian disease condition mediated by metalloproteinase activity which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically PFIZER INC. 2003-01-21 US disclosed
EP-0821671-B1 ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS PFIZER (US) 2000-12-27 EP disclosed
US-5861510-A Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors PFIZER INC (US) 1999-01-19 US disclosed
EP-0821671-A1 ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS PFIZER INC. (US) 1998-02-04 EP disclosed
WO-1996033172-A1 ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS PFIZER INC. (US) 1996-10-24 WO disclosed